Structure Of Solifenacin Succinate (Image 01)
Vesicare Suspension
Product Images NDC 51248-250
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Vesicare (NDC 51248-250). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Astellas Pharma Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Vesicare Ls (solifenacin Succinate) Oral Suspension 5 mg/5 mL (1 mg/ml) Carton Label (Image 02)
Vesicare Ls (solifenacin Succinate) Oral Suspension 5 mg/5 mL (1 mg/ml) Bottle Label (Image 03)
Each 1 mL of an oral suspension medication contains solifenacin succinate. The medication should be protected from light and dispensed in a light-resistant container by a pharmacist. The recommended storage temperature is between 15°C to 30°C (55 to 86°F) according to USP Controlled Room Oral Suspension guidelines, and the medication can be used for 28 days after the first opening. The medication is produced in Ireland and should be shaken well before use. The strength of the suspension is 1mg/mL.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
